Enhancement Proposals Presented by the Commission to Boost Accuracy of Information from Member States

Enhancement Proposals Presented by the Commission to Boost Accuracy of Information from Member States

In Germany, the use of medical cannabis remains prescription-only, a decision primarily driven by concerns for medical oversight, patient safety, and preventing abuse. The German Federal Ministry of Health's July 2025 draft amendment to the Medical Cannabis Act emphasizes the importance of in-person doctor consultations before cannabis flowers are dispensed and bans direct shipping to consumers [1][3].

This approach reflects regulatory priorities such as:

• Strengthening medical care by requiring personal contact with physicians (either in-person or home visits) to ensure proper patient assessment and to avoid abuse of digital prescription services [1][3].
• Preventing uncontrolled distribution by banning mail-order delivery of cannabis flowers and imposing penalties for violations [1][3].
• Maintaining strict regulatory frameworks to separate medical use from recreational use and to protect vulnerable groups, especially youth [1].

However, these regulatory hurdles have led to barriers in access and system inefficiencies. Cultivation associations, which can provide a secure and quality-controlled supply, including education and youth protection, face high bureaucratic and financial challenges [1]. Patients often encounter limited availability in local pharmacies, leading to supply shortages or high prices and, in some cases, resorting to the black market [5].

The in-person consultation requirement and lack of mail-order options impose extra costs and logistical challenges, especially for patients in rural areas, leading to concerns about the emergence of a two-tier healthcare system [5].

Alternatives for Secure and Standardized Medical Cannabis Supply

Cannabis cultivation associations (clubs) in Germany, although currently limited by regulation and operational difficulties, represent a promising model offering education, quality control, and secure distribution within a non-commercial framework with strict membership and security protocols [1].

Digital platforms facilitating telemedicine and online prescription services have improved access and inventory management. However, new draft amendments threaten these by requiring physical doctor visits and banning mail-order delivery, which patient groups and industry experts warn could reduce security of supply and push patients towards illicit markets [1][5].

The government is exploring legislative reforms to clarify and tighten regulations; however, stakeholders urge a balanced approach that maintains patient access, supply security, and quality control while avoiding over-restriction that could undermine progress achieved since cannabis was reclassified as a non-narcotic in 2024 [3][5].

After registration, a medical history is taken via a digital form. An approved doctor checks the suitability for cannabis therapy and issues a prescription if necessary. Upon request, the prescription is forwarded to a partner pharmacy, and the products are delivered directly to the patient [2].

Private cultivation of cannabis is possible, with a maximum of three flowering plants per person. Plants must be secured to prevent theft or access by unauthorized persons, especially children and young people. However, inaccurate dosage is a major concern with home cultivation due to the strong dose-dependent effects of cannabinoids [4].

Cultivation must strictly adhere to legal regulations to avoid fines or criminal consequences. Transfer of harvested cannabis remains prohibited. Cultivation is not recommended for patients due to variable THC and CBD content [4]. Adults aged 18 and over are allowed to possess up to 25 grams of dried cannabis [4].

Pharmacies and specialized digital providers like CanDoc play a central role in the professional production, secure distribution, and continuous monitoring of medical cannabis. These platforms offer a legally secure and hassle-free access to cannabis products of proven quality [2].

In conclusion, medical cannabis remains prescription-only in Germany, primarily due to regulatory efforts to ensure patient safety, proper medical evaluation, and prevent abuse. Alternatives like cultivation associations and telemedicine platforms exist but face bureaucratic constraints and potential legal rollbacks that challenge secure, standardized supply and patient access [1][3][5].

1. The use of medical cannabis in Germany is primarily regulated to maintain medical oversight, patient safety, and prevent abuse.
2. Strict regulations in Germany require personal contact with physicians to ensure proper patient assessment and prevent digital prescription service abuse.
3. Direct shipping of cannabis flowers to consumers is banned in Germany, aiming to prevent uncontrolled distribution.
4. Strengthening medical care involves in-person or home visits with physicians to avoid digital prescription service abuse.
5. In-person consultation requirements and lack of mail-order options pose extra costs and logistical challenges for patients, especially those in rural areas.
6. Cannabis cultivation associations in Germany, despite regulatory challenges, offer a secure, quality-controlled supply, education, and youth protection.
7. Changes in draft amendments threaten digital platforms, which facilitate telemedicine and online prescription services, by requiring physical doctor visits and banning mail-order delivery.
8. Limited availability of cannabis in local pharmacies can lead to supply shortages or high prices, driving some patients to the black market.
9. The government is exploring legislative reforms to regulate medical cannabis supply more clearly and tightly.
10. Stakeholders advocate for a balanced approach that maintains patient access, supply security, and quality control without undermining progress since cannabis was reclassified as a non-narcotic.
11. After registration, a medical history is taken via a digital form, and an approved doctor issues a prescription if necessary.
12. Partner pharmacies receive prescriptions and deliver cannabis products directly to patients.
13. Private cultivation of cannabis is allowed with security measures in place to prevent theft and unauthorized access.
14. Home cultivation poses concerns due to inaccurate dosage and variable THC and CBD content.
15. Cultivation must strictly adhere to legal regulations to avoid fines or criminal consequences.
16. Adults aged 18 and over are allowed to possess up to 25 grams of dried cannabis.
17. Pharmacies and platforms like CanDoc play a central role in the production, secure distribution, and continuous monitoring of medical cannabis.
18. These platforms provide a legally secure, hassle-free access to cannabis products of proven quality.
19. Medical cannabis remains an essential aspect of the industry, requiring careful consideration of “mental health,” “chronic diseases,” “respiratory conditions,” “digestive health,” “eye health,” “hearing,” “fitness and exercise,” “sexual health,” "autoimmune disorders," and “climate change” in its implementation.
20. In the realm of "health-and-wellness" and "workplace-wellness,” conversations about the impact of cannabis on "cardiovascular health," “cancer,” "neurological disorders," and “skin conditions” are prevalent.
21. "Energy," "finance," and "banking-and-insurance" sectors might have interests in the funding and support of medical cannabis research and distribution networks.
22. "Medicare" and "private-equity" firms could invest in ventures related to "medical-conditions," "cardiovascular-health," “respiratory conditions,” "neurological disorders," and "skin conditions."
23. Within the realm of "technology" and "fintech," innovations such as "cryptocurrencies" and "blockchain" could streamline medical cannabis transactions and inventory management.
24. "Aerospace" and "aviation" could explore the potential of cannabis applications in space and high-altitude scenarios, considering cerebral oxygen saturation and the effects of reduced air pressure.
25. "Real-estate" and "retail" industries should develop guidelines for retail spaces selling medical cannabis, ensuring accessibility, security, and a focus on local economies and small businesses.
26. "Transportation" and "public-transit," through policy and infrastructure, could support the safe transportation and access of medical cannabis patients, as well as addressing concerns about impaired driving.
27. "Entrepreneurship" and "leadership" in the industry should prioritize "diversity-and-inclusion" in hiring practices and executive positions, reflecting the diverse patient population and socioeconomic backgrounds.
28. As medical cannabis innovative market continues to grow, discussions surrounding "investing," "venture-capital," and "personal-finance" will become increasingly important for driving progress in the sector and reducing barriers to access.

Read also: